Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Panel Members Share Views on One Key Topic toward PMD Law Amendment; Next Meeting Scheduled Soon: Official
Yoichi Torii, director of the Pharmaceutical Safety and Environmental Health Bureau’s General Affairs Division said on September 20 that members of a health minister panel have reached an agreement on one of the three key topics for a possible amendment…
To read the full story
Related Article
- MHLW Panel Wraps Up 1st Round of Debates on PMD Law Amendment, Elaborate Discussions Slated to Start in September
July 26, 2018
- Industry Asked for Legislation for Conditional Early Approval and Sakigake Designation Scheme: MHLW Panel
May 11, 2018
- MHLW Panel to Kick Off Debates on Amendment of Pharmaceuticals and Medical Devices Law
April 5, 2018
REGULATORY
- ONODERA GT’s Parkinson’s Gene Therapy Gets Sakigake Tag
June 10, 2026
- Cabinet Approves Immunization Act Revision to Cover Antibody Drugs
June 10, 2026
- LDP Lawmakers Seek Routine HPV Vaccinations for Males by April 2027
June 10, 2026
- MHLW Lifts Part of Approval Conditions for Takeda’s Vyvanse
June 9, 2026
- Drug Makers Seek Govt Support for Immunoglobulin Plant Investments: LDP Hearing
June 9, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…